Literature DB >> 3128014

Phenacetin O-deethylation by human liver microsomes: kinetics and propranolol inhibition.

E M Gillam1, P E Reilly.   

Abstract

1. Phenacetin O-deethylation catalysed by human liver microcomes has been examined over a substrate concentration range of 2.5 to 700 microM using preparations of eight human liver samples. Michaelis-Menten kinetics described phenacetin oxidation satisfactorily in five of these samples; apparent Km values were in the range of 17.7 to 38.4 microM. 2. In the three other livers a single rectangular hyperbolic relationship did not describe the substrate saturation data adequately; analyses in these three cases requiring two classes of catalytic site. The apparent Km value for the higher affinity class of site in these three samples was within the range quoted above, but limitations imposed by assay sensitivity and phenacetin solubility obviated accurate characterization of the lower affinity class. 3. Estimates of Vmax for the high affinity class of site in the eight livers varied eleven-fold and there was no correlation between either Km or Vmax and microsomal cytochrome P-450 specific content, NADPH cytochrome c (P-450) reductase specific activity or ethylmorphine demethylase activity. 4. Propranolol was a potent competitive inhibitor of phenacetin deethylation with apparent Ki values of 2 to 7 microM describing its effect on the higher affinity class of activity. Propranolol was also an inhibitor of the lower affinity phenacetin deethylase identified in three of the livers, however the mechanism of inhibition could not be characterized. 5. These data suggest the possibility that propranolol oxidation may be mediated in part, by one or more human liver cytochrome P-450 species catalyzing phenacetin oxidation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128014     DOI: 10.3109/00498258809055140

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Characterization of Porcine Hepatic and Intestinal Drug Metabolizing CYP450: Comparison with Human Orthologues from A Quantitative, Activity and Selectivity Perspective.

Authors:  Wim Schelstraete; Laura De Clerck; Elisabeth Govaert; Joske Millecam; Mathias Devreese; Dieter Deforce; Jan Van Bocxlaer; Siska Croubels
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

2.  Unravelling the pharmacokinetics of aflatoxin B1: In vitro determination of Michaelis-Menten constants, intrinsic clearance and the metabolic contribution of CYP1A2 and CYP3A4 in pooled human liver microsomes.

Authors:  Orphélie Lootens; Marthe De Boevre; Elke Gasthuys; Jan Van Bocxlaer; An Vermeulen; Sarah De Saeger
Journal:  Front Microbiol       Date:  2022-08-29       Impact factor: 6.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.